湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 说明： 1、主营业务分行业情况中，"医疗业务及其他"为子公司永州方盛天鸿肿瘤医院 有限公司医疗服务业务收入、子公司重庆筱熊猫药业股份有限公司和湖南方盛锐新药业 有限公司（分别于 2024 年 4 月、6 月后不再纳入合并范围）医药销售业务收入、子公司 广东暨大基因药物工程研究中心有限公司的医药技术服务收入、子公司云南芙雅生物科 技有限公司植物提取产品收入； 证券代码：603998 证券简称：方盛制药 公告编号：2025-077 湖南方盛制药股份有限公司 2025年半年度经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第六号——医药制造》的 相关规定，湖南方盛制药股份有限公司（以下简称"公司"）现 将 2025 年上半年度主要经营数据披露如下（单位：元，人民币）： | | | ...

Group 1 - The core viewpoint of the news is that Fangsheng Pharmaceutical (603998) has shown a mixed performance in its latest financial results, with a decrease in total revenue but an increase in net profit [1] - As of August 25, 2025, Fangsheng Pharmaceutical's stock closed at 12.63 yuan, up 3.87%, with a trading volume of 637,500 hands and a transaction amount of 799 million yuan [1] - The company's latest quarterly report indicates total revenue of 418 million yuan, a year-on-year decrease of 4.62%, while net profit attributable to shareholders reached 88.26 million yuan, a year-on-year increase of 25.74% [1] Group 2 - The company has a liquidity ratio of 0.829 and a quick ratio of 0.511, with a debt-to-asset ratio of 44.14% [1] - Fangsheng Pharmaceutical has made investments in 42 companies and participated in 4,804 bidding projects, indicating active engagement in the market [2] - The company holds 115 trademark registrations and 62 patents, along with 169 administrative licenses, showcasing its commitment to intellectual property and regulatory compliance [2]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-074 湖南方盛制药股份有限公司 关于公司参与投资设立的并购基金对外出售投资 项目部分股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示：同系方盛投资的湖南珂信已将其持有的长沙珂信 51%的股权转 让至盈康生命，且盈康生命已支付相关转让价款。湖南珂信对回购价款及各期支付金额 进行调整，调整后，同系方盛预计将获得回购款 15,460.06 万元，湖南珂信将支付至同 系方盛的第一期回购款为 7,764.54 万元。2025 年 8 月 25 日，公司收到同系方盛向公司 分配项目处置款 7,764.54 万元； 风险提示：截至本公告披露日，公司对同系方盛的实缴出资尚有 2,085.46 万元 未收回。湖南珂信将持有的长沙珂信 51%的股权转让至盈康生命的交易已完成，但湖南 珂信能否完成业绩承诺继续向盈康生命转让长沙珂信 29%、20%的股权 ...

证券之星消息，8月22日中药板块较上一交易日上涨0.08%，太龙药业领涨。当日上证指数报收于 3825.76，上涨1.45%。深证成指报收于12166.06，上涨2.07%。中药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000650 | 仁和药业 | 6.65 | -5.27% | 316.23万 | 21.24亿 | | 603998 | 方盛制药 | 12.16 | -4.03% | 55.75万 | 6.85亿 | | 833266 | 生物谷 | 11.40 | -3.06% | 5.58万 | 6366.50万 | | 300147 | ST香雪 | 10.74 | -2.98% | 40.54万 | 4.43亿 | | 000590 | 启迪药业 | 12.44 | -2.43% | 11.51万 | 1.43亿 | | 002424 ...

Core Viewpoint - The company, Hunan Fangsheng Pharmaceutical Co., Ltd., will hold a half-year performance briefing on August 29, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in Q&A sessions [2][3][4]. Group 1: Meeting Details - The meeting is scheduled for August 29, 2025, from 09:00 to 10:00 [4]. - It will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from August 22 to August 28, 2025, through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants include the Chairwoman and General Manager, Ms. Zhou Xiaoli, Independent Director, Mr. Yuan Xiong, Chief Financial Officer, Ms. Cao Xiangqi, and Board Secretary, Mr. He Shi [4]. Group 3: Investor Participation - Investors can join the briefing online through the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [4][5]. - The company will address commonly asked questions during the session [3][5]. Group 4: Contact Information - For inquiries, investors can contact Ms. Wang Chaoxia at phone number 0731-88997135 or via the provided email addresses [5]. Group 5: Post-Meeting Access - After the briefing, investors can access the meeting's details and main content through the Shanghai Stock Exchange Roadshow Center [5].

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-073 湖南方盛制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 8 月 29 日（星期五）09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 湖南方盛制药股份有限公司（以下简称"公司"）将于 2025 年 8 月 29 日发布公司 2025 年半年度报告，为便于广大投资者更 全面深入地了解公司 2025 年半年度经营成果、财务状况，公司 计划于 2025 年 8 月 29 日（星期五）09:00-10:00 举行 2025 年半 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开， ...

Core Viewpoint - The hepatitis concept sector experienced a decline of 0.67%, with several companies facing significant losses, while a few companies saw gains, indicating a mixed performance in the market [1]. Group 1: Sector Performance - The hepatitis concept sector ranked among the top decliners, with companies like New Tian Pharmaceutical and Chengyi Pharmaceutical hitting the daily limit down [1]. - Notable decliners included Guangshantang and Weikang Pharmaceutical, while Renhe Pharmaceutical, Fangsheng Pharmaceutical, and Lifang Pharmaceutical were among the few that saw gains, with increases of 10.00%, 9.99%, and 4.76% respectively [1]. Group 2: Capital Flow - The hepatitis concept sector saw a net outflow of 2.295 billion yuan, with 95 stocks experiencing net outflows, and 7 stocks seeing outflows exceeding 100 million yuan [2]. - The stock with the highest net outflow was Furuishi, with a net outflow of 484.35 million yuan, followed by Guangshantang and Hanyu Pharmaceutical with outflows of 297.48 million yuan and 212.30 million yuan respectively [2]. Group 3: Individual Stock Performance - Furuishi's stock declined by 1.29% with a turnover rate of 21.35% and a significant net outflow of 484.35 million yuan [2]. - Guangshantang's stock fell by 8.69% with a turnover rate of 12.48% and a net outflow of 297.48 million yuan [2]. - Chengyi Pharmaceutical saw a decline of 9.99% with a turnover rate of 16.81% and a net outflow of 581.07 million yuan [3].

证券之星消息，8月20日中药板块较上一交易日上涨0.59%，天目药业领涨。当日上证指数报收于 3766.21，上涨1.04%。深证成指报收于11926.74，上涨0.89%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600671 | 天目药业 | 18.58 | 10.01% | 3.52万 | | 6344.92万 | | 000650 | 仁和药业 | 6.38 | 10.00% | 31.97万 | | 2.04亿 | | 603998 | 方盛制药 | 12.66 | 9.99% | 1 112.37万 | | 13.90 Z | | 300391 | *ST长药 | 4.47 | 5.18% | 21.10万 | | 9284.64万 | | 600285 | 羚锐制药 | 24.25 | 4.66% | 25.69万 | | 6.09亿 | | 300147 | ST香雪 | 11.02 | 4.55% | 79.62万 | | 8.9 ...

Group 1 - The Science and Technology Innovation 50 Index rose over 3%, reaching a new high for the year, driven by a collective surge in chip stocks [1] - Companies such as Jimin Health, Hanzhong Precision Machinery, and Kesen Technology have seen consecutive trading gains, with Jimin Health achieving a five-day streak [1] - The AI server market is dominated by Inspur Information, which holds over 50% market share in China and has reported a 64.39% year-on-year increase in net profit for the first quarter [1] Group 2 - The domestic leading companies are making significant advancements, with Nvidia reportedly developing an AI chip specifically for the Chinese market [3] - Companies like Fullchai Power and Yuanlin Co. have also seen consecutive trading gains, indicating strong market performance [3] - The company Guangxin Technology is a leader in optical modules and has partnered with Cisco to launch a 1.6T silicon optical module [3] Group 3 - The domestic automotive sector is witnessing significant developments, with China FAW planning to acquire approximately 10% of Leap Motor [6] - Companies like Mould Technology and Shentong Express are also making strides, with Mould Technology providing components for new energy vehicles [6] - The automotive thermal management sector is led by companies like Hanzhong Precision Machinery, which specializes in compressors and refrigeration products [8] Group 4 - The pharmaceutical industry is seeing a surge in domestic innovative drugs going global, with Tianmu Pharmaceutical being the first listed company in traditional Chinese medicine [7] - Companies like Huahai Pharmaceutical are advancing in the development of innovative drugs, with over 20 projects currently in research [7] - The automotive passive safety system sector is represented by companies like Songyuan Safety, which reported a 30.85% year-on-year increase in net profit [7]

证券日报网讯 8月19日晚间，方盛制药发布公告称，公司拟以人民币8，000万元受让中国药科大学与中 国医学科学院药物研究所持有的化药1类创新药物IMM-H024原料药及制剂项目的专利权，后续将按相 关约定节点分期付款。本次交易不构成关联交易，不构成重大资产重组；本次交易已经公司第六届董事 会2025年第五次临时会议审议通过，无需提交股东会审议。 （文章来源：证券日报） ...